Meru Biotechnologies Revenue and Competitors
Estimated Revenue & Valuation
- Meru Biotechnologies's estimated annual revenue is currently $930k per year.
- Meru Biotechnologies's estimated revenue per employee is $155,000
Employee Data
- Meru Biotechnologies has 6 Employees.
- Meru Biotechnologies grew their employee count by 20% last year.
Meru Biotechnologies's People
Name | Title | Email/Phone |
---|
Meru Biotechnologies Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.4M | 9 | -10% | N/A | N/A |
#2 | $4.3M | 28 | 4% | N/A | N/A |
#3 | $1.1M | 7 | 0% | N/A | N/A |
#4 | $3.5M | 45 | -52% | $56.5M | N/A |
#5 | $0.3M | 2 | 0% | N/A | N/A |
#6 | $4.5M | 29 | 21% | N/A | N/A |
#7 | $1.9M | 12 | 9% | N/A | N/A |
#8 | $7M | 45 | 5% | N/A | N/A |
#9 | $6.7M | 43 | 5% | N/A | N/A |
#10 | $2M | 13 | -13% | N/A | N/A |
What Is Meru Biotechnologies?
Understanding and measuring biomolecular binding interactions remains a critical component of biochemical research, drug discovery, and diagnostics development. Despite enormous emphasis on collecting biologically relevant binding affinity data, many existing methods struggle to sensitively measure these interactions through chemical manipulation of one or more binding partner. Meru Biotechnologies’ Free Solution Analysis (FSA)combines the strengths of existing label-free approaches in a straightforward analytical platform, powered by advancements in Compensated Interferometry, which uses a single laser to measure experimental and reference samples in the same microfluidic channel simultaneously. FSA’s sensitivity rivals methods that use fluorescence and eliminates the need for surface immobilization strategies.
keywords:N/AN/A
Total Funding
6
Number of Employees
$930k
Revenue (est)
20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.4M | 6 | 0% | N/A |
#2 | $0.4M | 6 | -14% | N/A |
#3 | $0.4M | 6 | 50% | N/A |
#4 | $0.4M | 6 | 0% | N/A |
#5 | $0.2M | 6 | -14% | $2.4M |